ag亚娱

Be the most trusted biotech company

2019-03-19

The 2nd Combination Immunotherapy of Henlius Received Notification of Acceptance
2019-03-01

Official Announcement! Mr. WenjieZhang is Appointed as SVP and CCO of Henlius
2019-02-25

Henlius Receives NMPA Approval for Its First Product HLX01 –The Beginning of a New Era for Biosimilar
2019-02-12

New progress! Henlius HLX22 Received Clinical Approval from NMPA
2019-01-29

Henlius Completed Phase 1/2 Study of Its Rituximab Injection for Rheumatoid Arthritis
2019-01-24

Henlius Adalimumab Received Acceptance of New Drug Application
2018-11-29

Henlius Completed Data Analysis of the Phase 1 Study for Its HLX03
2018-11-26

Henlius HLX22 Received IND Application Acceptance Notification from NMPA
2018-11-16

Henlius Successfully Held Its Second Scientific Advisory Board (SAB) Meeting in California